Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give More Than 350 Flagstaff Children New Winter Coats[9:30:00 AM ET]FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give 350 Bay City Children New Winter Coats[9:30:00 AM ET]APH$80.00+1.79(+2.29%)Industrial Growth Partners Announces Sale of AdvancedPCB Industrial Growth Partners ("IGP") is pleased to announce that it has entered into a definitive agreement to sell AdvancedPCB Holdings, LLC...[9:27:00 AM ET]BLGO$0.07-0.00(-3.62%)BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success[9:25:00 AM ET]TWOSF$0.24-0.00(-0.04%)T2 Metals to Attend the 52nd Annual New Orleans Investment Conference[9:25:00 AM ET]MOB$3.32+0.03(+0.91%)Mobilicom to Showcase Cybersecure Portfolio Highlighting Newly Launched SwarmiX at ARC WEPTAC Conference[9:22:00 AM ET]COSM$0.25+0.02(+6.82%)Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target[9:20:00 AM ET]MGN$2.83-0.23(-7.52%)Megan Holdings Limited Announces Pricing of Up to $7.5 Million Follow-on Public Offering[9:20:00 AM ET]ADSE$9.36+0.06(+0.65%)ADS-TEC Energy Advances One of Europe's Largest Battery Storage Projects as Building Permit Nears[9:18:00 AM ET]ELS$58.45-1.04(-1.75%)ELS Declares Fourth Quarter 2026 Dividend On October 27, 2026, the Board of Directors of Equity LifeStyle Properties, Inc. (NYSE: ELS) (referred to herein as "we," "us," and "our") declared a ...[9:18:00 AM ET]IREN$27.27-0.18(-0.64%)IREN and Wingspire Equipment Finance Complete $363 Million Financing for High-Density AI Compute Assets[9:17:00 AM ET]GSAT$83.91+0.01(+0.01%)XCOM RAN Wins the Gold Stevie® 2026 Award for Technology Excellence[9:16:00 AM ET]CYAB$0.13-0.00(-0.53%)Cyabra Finds Coordinated Inauthentic Activity in Five of Six Competitive Midterm Races, Affecting Candidates from Both Parties[9:15:00 AM ET]AIBT$0.000.00(0.00%)AIBotics Provides PHILL ROBOT™ Manufacturing Update as 3DX Industries Supports Five-Unit Pilot[9:15:00 AM ET]LGVN$1.79+0.06(+3.42%)Longeveron Announces Engagement of Lucid Capital Markets[9:15:00 AM ET]QNC$1.10+0.01(+0.92%)Quantum eMotion to Showcase Quantum-Safe Cybersecurity Portfolio at World Quantum Cannes Festival November 17-18, 2026[9:15:00 AM ET]

RNXT · NASDAQ

RenovoRx, Inc.

$1.38 -0.01 (-0.72%)

Company overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$62.3M
Employees
10
Headquarters
Mountain View, CA
Website
renovorx.com
CEO
Shaun R. Bagai
Listed
August 26, 2021
P/E
-4.17
Dividend yield
0.00%

Company financials

Revenue
$1.5M
Gross profit
$1.2M
Operating income
-$12.9M
EBITDA
-$12.9M
Net income
-$12.3M
EPS
-$0.34
Total assets
$14M
Total debt
$78,000
Gross margin
78.71%
Net margin
-823.98%
Earnings yield
-23.96%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

0.701.191.682.172.66
RNXT 1D NASDAQ O1.33H1.43L1.30C1.39+0.08 (+6.11%)Vol57.04K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
RNXTRenovoRx, Inc. Press release RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum GlobeNewswire
RNXTRenovoRx, Inc. Press release RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 GlobeNewswire
RNXTRenovoRx, Inc. Press release RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer GlobeNewswire
RNXTRenovoRx, Inc. Press release RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th GlobeNewswire
RNXTRenovoRx, Inc. Press release RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment GlobeNewsWire
RNXTRenovoRx, Inc. Stock news RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers MarketBeat
RNXTRenovoRx, Inc. Stock news RenovoRx Q2 Earnings Call Highlights MarketBeat
RNXTRenovoRx, Inc. Stock news RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
RNXTRenovoRx, Inc. Press release RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting GlobeNewsWire
RNXTRenovoRx, Inc. Press release RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th GlobeNewsWire
RNXTRenovoRx, Inc. Stock news RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates Zacks Investment Research
RNXTRenovoRx, Inc. Press release RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter GlobeNewsWire
See more
FAQ

Questions about RenovoRx, Inc.

What does RenovoRx, Inc. do?
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
What is RNXT's market cap?
RenovoRx, Inc. (RNXT) is a listed stock with a live quote. The latest market cap on this page is $62.3M.
Where is RenovoRx, Inc. headquartered?
RenovoRx, Inc. is headquartered in Mountain View, CA.
How do I get RNXT news from the API?
Call GET /v1/news?tickers=RNXT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does RNXT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RNXT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the RNXT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs